Can I Take Glutathione with Praluent (Alirocumab)?

How Alirocumab Is Handled by the Body

Alirocumab binds PCSK9 and prevents PCSK9 from promoting LDL-receptor degradation. More LDL receptors remain available on liver cells to clear LDL cholesterol. The current DailyMed Praluent label describes this mechanism and the drug's pharmacokinetics [1].

Monoclonal Antibodies Follow a Unique Clearance Pathway

Monoclonal antibodies do not follow the same clearance pathways as most small-molecule drugs. Alirocumab has a saturable elimination phase related to PCSK9 binding and a non-saturable proteolytic phase in which the protein is broken into peptides and amino acids [1]. Population pharmacokinetic research on therapeutic monoclonal antibodies describes the same combination of target-mediated disposition and protein catabolism 2.

The label also reports that repeated alirocumab administration did not produce relevant changes in atorvastatin or rosuvastatin concentrations. This supports the conclusion that CYP enzymes and transporters such as P-glycoprotein and OATP are not central to alirocumab disposition [1]. It does not directly test glutathione.

What the Label Does and Does Not Establish

The label does not list glutathione as a contraindication or a drug interaction [1]. It also does not report a dedicated study of Praluent with oral, liposomal, sublingual, or IV glutathione. The accurate conclusion is therefore narrower than "proven safe": no glutathione-specific interaction appears in labeling, and direct combination evidence is absent.

What Human Glutathione Studies Show

Glutathione is an endogenous tripeptide involved in redox regulation. Cells synthesize it from cysteine, glutamate, and glycine. A biochemical review describes its protective roles, biosynthesis, and the limits of using blood measurements as a proxy for tissue glutathione 3.

Oral Results Depend on the Study

A six-month randomized, double-blind, placebo-controlled trial assigned 54 healthy adults to placebo, 250 mg/day, or 1,000 mg/day of oral glutathione. At six months, several measured compartments increased by 30 to 35% in the high-dose group, while lower-dose responses were smaller and varied by compartment 4.

A separate four-week randomized trial of 500 mg twice daily in 40 healthy adults found no significant change in glutathione status or the measured oxidative-stress biomarkers 5. These different results are a reason to avoid assigning one universal absorption percentage to every formulation.

IV Products Are a Separate Evidence Question

IV administration cannot be treated as interchangeable with an oral supplement. Our review found no direct study of IV glutathione given with alirocumab. A mechanistic argument alone cannot establish the safety of that combination.

Glutathione Is Not a Replacement for Lipid-Lowering Therapy

The oral glutathione trials above measured glutathione stores or oxidative-stress markers, not whether glutathione can reproduce alirocumab's LDL-lowering or cardiovascular effects. Glutathione should not be used as a substitute for Praluent or another prescribed lipid-lowering treatment.

Interaction Evidence: Supported Findings and Unknowns

Alirocumab Outcomes That Are Actually Documented

In ODYSSEY LONG TERM, 2,341 patients at high cardiovascular risk received alirocumab or placebo on top of other lipid-lowering therapy. At week 24, the alirocumab group had a 61.0% mean LDL-C reduction from baseline 6.

ODYSSEY OUTCOMES randomized 18,924 patients after an acute coronary syndrome and followed them for a median of 2.8 years. A primary endpoint event occurred in 9.5% of the alirocumab group and 11.1% of the placebo group, corresponding to a hazard ratio of 0.85 (95% CI 0.78 to 0.93) 7.

For homozygous familial hypercholesterolemia, ODYSSEY HoFH randomized 69 patients. At week 12, LDL-C changed by minus 26.9% from baseline with alirocumab and increased by 8.6% with placebo; the least-squares mean difference was minus 35.6 percentage points 8. These trial results establish alirocumab's effects. They do not establish an effect for glutathione.

Practical Recommendations for Patients Taking Both

The evidence supports a short, concrete checklist rather than a blanket yes or no.

Tell Your Prescriber Before Starting

Record the specific form of glutathione, dose, brand, and frequency. Oral capsules and IV products should not be grouped together. Add the product to the medication list so a new symptom or unexpected LDL-C change can be assessed against the correct exposure.

Continue Scheduled LDL-C Monitoring

The 2018 AHA/ACC cholesterol guideline recommends checking adherence and LDL response 4 to 12 weeks after starting or adjusting a statin, then every 3 to 12 months as needed 9. For Praluent specifically, the current label says LDL-C may be measured as early as four weeks after treatment starts; for 300 mg every four weeks, measure LDL-C immediately before the next scheduled dose [1]. Do not assume glutathione explains an unexpected result. First verify the Praluent schedule, injection technique, other medications, and blood-draw timing.

Do Not Invent a Separation Window

The Praluent label does not specify a timing interval for glutathione [1]. No direct study proves that taking the products two hours apart, on different days, or at the same time changes alirocumab exposure. Follow the prescribed injection schedule instead of creating an unsupported timing rule.

Use the Labeled Injection Instructions

The current label instructs patients to inject into the thigh, abdomen, or upper arm, rotate sites, and avoid skin that is tender, bruised, red, or hard [1]. These instructions are evidence-based. A universal 24-hour rule for topical glutathione near the injection site is not in the label and should not be presented as fact.

The Evidence Gap: What Research Still Needs to Answer

No randomized trial identified in our review enrolled alirocumab recipients and assigned glutathione versus placebo. The label and known clearance pathways lower concern for a classic CYP-mediated interaction, but the evidence cannot quantify risk for a specific supplement formulation. Useful future research would measure alirocumab exposure, LDL-C response, adverse events, and oral versus IV glutathione separately.